A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
Files
(Published version)
Date
2013
Authors
Mellor, J.
Brown, M.
Irving, H.
Zalcberg, J.
Dobrovic, A.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Journal of Hematology and Oncology, 2013; 6(1):1-10
Statement of Responsibility
James D Mellor, Michael P Brown, Helen R Irving, John R Zalcberg and Alexander Dobrovic
Conference Name
Abstract
Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism of action of therapeutic monoclonal antibodies (mAbs) such as cetuximab, rituximab and trastuzumab. Fc gamma receptors (FcgR) on human white blood cells are an integral part of the ADCC pathway. Differential response to therapeutic mAbs has been reported to correlate with specific polymorphisms in two of these genes: FCGR2A (H131R) and FCGR3A (V158F). These polymorphisms are associated with differential affinity of the receptors for mAbs. This review critically examines the current evidence for genotyping the corresponding single nucleotide polymorphisms (SNPs) to predict response to mAbs in patients with cancer.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2013 Mellor et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.